HPV16 antibodies as risk factors for oropharyngeal cancer and their association with tumor HPV and smoking status

Karen Anderson, Kristina R. Dahlstrom, Julia N. Cheng, Rizwan Alam, Guojun Li, Qingyi Wei, Neil D. Gross, Diego Chowell, Marshall Posner, Erich M. Sturgis

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Background Antibodies (Abs) to the HPV16 proteome increase risk for HPV-associated OPC (HPVOPC). The goal of this study was to investigate the association of a panel of HPV16 Abs with risk for OPC as well as the association of these Abs with tumor HPV and smoking status among patients with OPC. Methods IgG Abs to the HPV16 antigens E1, E2, E4, E5, E6, E7, L1, L2 were quantified using a programmable ELISA assay. Sera were obtained from 258 OPC patients at diagnosis and 250 healthy controls. HPV16 tumor status was measured by PCR for 137 cases. Multivariable logistic regression was used to calculate odds ratios for the association of HPV16 Abs with risk for OPC. Results HPV16 E1, E2, E4, E5, E6, E7 and L1-specific IgG levels were elevated in OPC patients compared to healthy controls (p < 0.05). After multivariable adjustment, Ab positivity for NE2, CE2, E6, and/or E7 was associated with OPC risk (OR [95% CI], 249.1 [99.3-624.9]). Among patients with OPC, Ab positivity for these antigens was associated with tumor HPV status, especially among never or light smokers (OR [95% CI], 6.5 [2.1-20.1] and OR [95% CI], 17.5 [4.0-77.2], respectively). Conclusions Antibodies to HPV16 proteins are associated with increased risk for HPVOPC. Among patients with OPC, HPV16 Abs are associated with tumor HPV status, in particular among HPV positive patients with no or little smoking history.

Original languageEnglish (US)
Pages (from-to)662-667
Number of pages6
JournalOral Oncology
Volume51
Issue number7
DOIs
StatePublished - Jul 1 2015

Fingerprint

Oropharyngeal Neoplasms
Smoking
Antibodies
Neoplasms
Immunoglobulin G
Neoplasm Antibodies
Social Adjustment
Proteome
Logistic Models
History
Enzyme-Linked Immunosorbent Assay
Odds Ratio
Antigens
Polymerase Chain Reaction
Serum

Keywords

  • Antibodies
  • Biomarker
  • Head and neck cancer
  • HPV
  • Oropharyngeal cancer
  • Serology

ASJC Scopus subject areas

  • Oncology
  • Oral Surgery
  • Cancer Research

Cite this

HPV16 antibodies as risk factors for oropharyngeal cancer and their association with tumor HPV and smoking status. / Anderson, Karen; Dahlstrom, Kristina R.; Cheng, Julia N.; Alam, Rizwan; Li, Guojun; Wei, Qingyi; Gross, Neil D.; Chowell, Diego; Posner, Marshall; Sturgis, Erich M.

In: Oral Oncology, Vol. 51, No. 7, 01.07.2015, p. 662-667.

Research output: Contribution to journalArticle

Anderson, K, Dahlstrom, KR, Cheng, JN, Alam, R, Li, G, Wei, Q, Gross, ND, Chowell, D, Posner, M & Sturgis, EM 2015, 'HPV16 antibodies as risk factors for oropharyngeal cancer and their association with tumor HPV and smoking status', Oral Oncology, vol. 51, no. 7, pp. 662-667. https://doi.org/10.1016/j.oraloncology.2015.04.011
Anderson, Karen ; Dahlstrom, Kristina R. ; Cheng, Julia N. ; Alam, Rizwan ; Li, Guojun ; Wei, Qingyi ; Gross, Neil D. ; Chowell, Diego ; Posner, Marshall ; Sturgis, Erich M. / HPV16 antibodies as risk factors for oropharyngeal cancer and their association with tumor HPV and smoking status. In: Oral Oncology. 2015 ; Vol. 51, No. 7. pp. 662-667.
@article{670955aea7e74eff815a3d4d8cd570cf,
title = "HPV16 antibodies as risk factors for oropharyngeal cancer and their association with tumor HPV and smoking status",
abstract = "Background Antibodies (Abs) to the HPV16 proteome increase risk for HPV-associated OPC (HPVOPC). The goal of this study was to investigate the association of a panel of HPV16 Abs with risk for OPC as well as the association of these Abs with tumor HPV and smoking status among patients with OPC. Methods IgG Abs to the HPV16 antigens E1, E2, E4, E5, E6, E7, L1, L2 were quantified using a programmable ELISA assay. Sera were obtained from 258 OPC patients at diagnosis and 250 healthy controls. HPV16 tumor status was measured by PCR for 137 cases. Multivariable logistic regression was used to calculate odds ratios for the association of HPV16 Abs with risk for OPC. Results HPV16 E1, E2, E4, E5, E6, E7 and L1-specific IgG levels were elevated in OPC patients compared to healthy controls (p < 0.05). After multivariable adjustment, Ab positivity for NE2, CE2, E6, and/or E7 was associated with OPC risk (OR [95{\%} CI], 249.1 [99.3-624.9]). Among patients with OPC, Ab positivity for these antigens was associated with tumor HPV status, especially among never or light smokers (OR [95{\%} CI], 6.5 [2.1-20.1] and OR [95{\%} CI], 17.5 [4.0-77.2], respectively). Conclusions Antibodies to HPV16 proteins are associated with increased risk for HPVOPC. Among patients with OPC, HPV16 Abs are associated with tumor HPV status, in particular among HPV positive patients with no or little smoking history.",
keywords = "Antibodies, Biomarker, Head and neck cancer, HPV, Oropharyngeal cancer, Serology",
author = "Karen Anderson and Dahlstrom, {Kristina R.} and Cheng, {Julia N.} and Rizwan Alam and Guojun Li and Qingyi Wei and Gross, {Neil D.} and Diego Chowell and Marshall Posner and Sturgis, {Erich M.}",
year = "2015",
month = "7",
day = "1",
doi = "10.1016/j.oraloncology.2015.04.011",
language = "English (US)",
volume = "51",
pages = "662--667",
journal = "Oral Oncology",
issn = "1368-8375",
publisher = "Elsevier Limited",
number = "7",

}

TY - JOUR

T1 - HPV16 antibodies as risk factors for oropharyngeal cancer and their association with tumor HPV and smoking status

AU - Anderson, Karen

AU - Dahlstrom, Kristina R.

AU - Cheng, Julia N.

AU - Alam, Rizwan

AU - Li, Guojun

AU - Wei, Qingyi

AU - Gross, Neil D.

AU - Chowell, Diego

AU - Posner, Marshall

AU - Sturgis, Erich M.

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Background Antibodies (Abs) to the HPV16 proteome increase risk for HPV-associated OPC (HPVOPC). The goal of this study was to investigate the association of a panel of HPV16 Abs with risk for OPC as well as the association of these Abs with tumor HPV and smoking status among patients with OPC. Methods IgG Abs to the HPV16 antigens E1, E2, E4, E5, E6, E7, L1, L2 were quantified using a programmable ELISA assay. Sera were obtained from 258 OPC patients at diagnosis and 250 healthy controls. HPV16 tumor status was measured by PCR for 137 cases. Multivariable logistic regression was used to calculate odds ratios for the association of HPV16 Abs with risk for OPC. Results HPV16 E1, E2, E4, E5, E6, E7 and L1-specific IgG levels were elevated in OPC patients compared to healthy controls (p < 0.05). After multivariable adjustment, Ab positivity for NE2, CE2, E6, and/or E7 was associated with OPC risk (OR [95% CI], 249.1 [99.3-624.9]). Among patients with OPC, Ab positivity for these antigens was associated with tumor HPV status, especially among never or light smokers (OR [95% CI], 6.5 [2.1-20.1] and OR [95% CI], 17.5 [4.0-77.2], respectively). Conclusions Antibodies to HPV16 proteins are associated with increased risk for HPVOPC. Among patients with OPC, HPV16 Abs are associated with tumor HPV status, in particular among HPV positive patients with no or little smoking history.

AB - Background Antibodies (Abs) to the HPV16 proteome increase risk for HPV-associated OPC (HPVOPC). The goal of this study was to investigate the association of a panel of HPV16 Abs with risk for OPC as well as the association of these Abs with tumor HPV and smoking status among patients with OPC. Methods IgG Abs to the HPV16 antigens E1, E2, E4, E5, E6, E7, L1, L2 were quantified using a programmable ELISA assay. Sera were obtained from 258 OPC patients at diagnosis and 250 healthy controls. HPV16 tumor status was measured by PCR for 137 cases. Multivariable logistic regression was used to calculate odds ratios for the association of HPV16 Abs with risk for OPC. Results HPV16 E1, E2, E4, E5, E6, E7 and L1-specific IgG levels were elevated in OPC patients compared to healthy controls (p < 0.05). After multivariable adjustment, Ab positivity for NE2, CE2, E6, and/or E7 was associated with OPC risk (OR [95% CI], 249.1 [99.3-624.9]). Among patients with OPC, Ab positivity for these antigens was associated with tumor HPV status, especially among never or light smokers (OR [95% CI], 6.5 [2.1-20.1] and OR [95% CI], 17.5 [4.0-77.2], respectively). Conclusions Antibodies to HPV16 proteins are associated with increased risk for HPVOPC. Among patients with OPC, HPV16 Abs are associated with tumor HPV status, in particular among HPV positive patients with no or little smoking history.

KW - Antibodies

KW - Biomarker

KW - Head and neck cancer

KW - HPV

KW - Oropharyngeal cancer

KW - Serology

UR - http://www.scopus.com/inward/record.url?scp=84930634108&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930634108&partnerID=8YFLogxK

U2 - 10.1016/j.oraloncology.2015.04.011

DO - 10.1016/j.oraloncology.2015.04.011

M3 - Article

C2 - 25957822

AN - SCOPUS:84930634108

VL - 51

SP - 662

EP - 667

JO - Oral Oncology

JF - Oral Oncology

SN - 1368-8375

IS - 7

ER -